MBB Public Markets I LLC bought a new stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 7,748 shares of the medical research company’s stock, valued at approximately $1,061,000.
Several other large investors have also recently bought and sold shares of the stock. Dark Forest Capital Management LP raised its stake in Quest Diagnostics by 560.2% during the 2nd quarter. Dark Forest Capital Management LP now owns 13,501 shares of the medical research company’s stock valued at $1,848,000 after purchasing an additional 11,456 shares during the last quarter. APG Asset Management N.V. increased its holdings in Quest Diagnostics by 13.5% in the 2nd quarter. APG Asset Management N.V. now owns 363,453 shares of the medical research company’s stock valued at $46,419,000 after buying an additional 43,308 shares during the period. AQR Capital Management LLC increased its holdings in Quest Diagnostics by 18.6% in the 2nd quarter. AQR Capital Management LLC now owns 147,469 shares of the medical research company’s stock valued at $20,186,000 after buying an additional 23,150 shares during the period. AXA S.A. increased its holdings in Quest Diagnostics by 564.7% in the 2nd quarter. AXA S.A. now owns 14,603 shares of the medical research company’s stock valued at $1,999,000 after buying an additional 12,406 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Quest Diagnostics in the 2nd quarter valued at $814,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, SVP Mark E. Delaney sold 420 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total value of $60,093.60. Following the transaction, the senior vice president now owns 5,019 shares of the company’s stock, valued at approximately $718,118.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, SVP Karthik Kuppusamy sold 1,990 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $153.26, for a total value of $304,987.40. Following the transaction, the senior vice president now owns 11,459 shares of the company’s stock, valued at approximately $1,756,206.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Mark E. Delaney sold 420 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $143.08, for a total transaction of $60,093.60. Following the completion of the transaction, the senior vice president now directly owns 5,019 shares in the company, valued at approximately $718,118.52. The disclosure for this sale can be found here. Insiders own 0.79% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Report on Quest Diagnostics
Quest Diagnostics Stock Up 0.3 %
Shares of NYSE DGX opened at $155.25 on Tuesday. The firm’s 50-day simple moving average is $151.29 and its 200 day simple moving average is $141.97. The company has a market cap of $17.25 billion, a price-to-earnings ratio of 20.90, a price-to-earnings-growth ratio of 2.80 and a beta of 0.89. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57. Quest Diagnostics Incorporated has a 12-month low of $119.59 and a 12-month high of $159.36.
Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its quarterly earnings results on Tuesday, July 23rd. The medical research company reported $2.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.31 by $0.04. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.39 billion. Quest Diagnostics had a net margin of 8.99% and a return on equity of 15.35%. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.30 EPS. On average, research analysts expect that Quest Diagnostics Incorporated will post 8.89 earnings per share for the current fiscal year.
Quest Diagnostics Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.93%. The ex-dividend date of this dividend is Friday, October 4th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 40.38%.
Quest Diagnostics Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Read More
- Five stocks we like better than Quest Diagnostics
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- TJX Stock: A Buying Opportunity Before the Holiday Rush
- Health Care Stocks Explained: Why You Might Want to Invest
- Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge
- Insider Trading – What You Need to Know
- Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth
Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGX – Free Report).
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.